跳至主要内容
临床试验/NCT05337774
NCT05337774终止1 期

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Life Molecular Imaging SA1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2021年6月7日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
发起方
入组人数
18
试验地点
1
主要终点
Tau deposition in the brain as measured with PI-2620 PET

研究概览

简要总结

The main objective of this interdisciplinary study is to develop an understanding of the molecular imaging features of blast-related mild traumatic brain injury (mTBI) in military personnel, while helping to establish assessment tools that may be of use in diagnosis, determining prognosis, and in future therapeutic clinical trials. Additionally, the objective is to evaluate feasibility of [18F]PI-2620 in the assessment TBI.

详细描述

The main objective of this interdisciplinary study is to develop an understanding of the molecular imaging features of blast-related mild traumatic brain injury (mTBI) in military personnel, while helping to establish assessment tools that may be of use in diagnosis, determining prognosis, and in future therapeutic clinical trials. Additionally, the objective is to evaluate feasibility of [18F]PI-2620 in the assessment TBI. This particular tracer has been shown to be effective in localizing tau deposition. [18F]PI-2620 has not yet received FDA approval for routine clinical use and for the purpose of this study is considered an Investigational New Drug (IND) by the FDA.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
25 Years 至 54 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Right-handed
  • Agree to participate in ALL study procedures
  • English speaking
  • Must be able to identify a study partner who is well acquainted with the participant for at least 2 years, to answer questions either in person or over the telephone about the participants' activities of daily living, and to corroborate behavioral and cognitive problems and history of brain injury
  • History of combat deployment
  • For blast-related mTBI group: must be active duty or DEERS-eligible, currently or formerly enrolled in the 4 week intensive outpatient program at NICoE, have experienced 1 or more blast-related mTBIs during tours of duty and report experiencing changes in mood, behavioral or cognitive problems (blast-related mTBI considered here and confirmed in EMR as: blast exposure from explosive device resulting in mTBI which fits criteria defined by VA DoD mTBI guidelines which include at least one of: at time of injury - LOC 0-30 minutes, AOC up to 24hrs, PTA 0-1 day, GCS 13-15)
  • DEERS-eligible for all participants
  • For control group 1: history of mTBI with no blast-related mTBIs (as confirmed in EMR and/or by the BISQ and QCube)
  • For control group 2: No lifetime history of TBI (as confirmed by the BISQ and/or EMR)

排除标准

  • Had a moderate or severe brain injury that required hospitalization
  • Significant systemic illness or unstable medical conditions including: uncontrolled diabetes mellitus, uncorrected hypothyroidism or hyperthyroidism, or systemic cancer
  • Diagnosis of schizophrenia, psychosis, or other psychological disorder (Note: blast-related mTBI group will not be excluded if they have a stable diagnosis of post-traumatic stress disorder, depression and anxiety resulting from their military experience; disorders existing prior to military service will serve as an exclusion)
  • Current and active alcohol or substance abuse or dependence (DSM V criteria) within the past 6 months
  • Clinically significant laboratory test abnormalities (such as hematology, chemistry, urinalysis, ECG) or significant impairment of liver or renal function
  • Significant cerebrovascular disease (such as TIA, stroke) or cardiovascular disease (such as uncontrolled hypertension, atrial fibrillation)
  • Impairment of visual or auditory acuity sufficient to interfere with completion of study procedures
  • Education level < 10 years
  • The presence of any MRI-incompatible prostheses or ferromagnetic metal, or any other condition that would preclude ability to undergo MRI or PET (such as claustrophobia or obesity, >350 lbs and/or unable to fit in scanners)
  • History of risk factors for torsade de pointes or take drugs known to prolong the QT interval
  • Had 2 or more PET scans in the last year, or other significant exposure to radiation (i.e. radiation therapy)
  • Diagnosis of neurodegenerative or neurological diseases and dementia (other than CTE) such as Alzheimer's disease, Parkinson's disease, vascular dementia, Huntington's disease, Pick's disease, Lewy Body Dementia, frontotemporal dementia, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, or multiple sclerosis

研究组 & 干预措施

Blast-related mTBI group

Experimental

Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).

干预措施: [18F]PI-2620 (Drug)

mTBI not blast-related (control group 1)

Experimental

Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).

干预措施: [18F]PI-2620 (Drug)

no history of TBI (control group 2)

Experimental

Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).

干预措施: [18F]PI-2620 (Drug)

结局指标

主要结局

Tau deposition in the brain as measured with PI-2620 PET

时间窗: 1 day

Tau deposition in the brain of military personnel with blast-related mTBI, non-blast mTBI or no history of TBI will be measured with PI-2620 using positron emission tomography.

Amyloid deposition in the brain as measured with Florbetaben PET

时间窗: 1 day

Amyloid deposition in the brain of military personnel with blast-related mTBI, non-blast mTBI or no history of TBI will be measured with Florbetaben using positron emission tomography.

次要结局

  • Correlation of brain MR imaging with PI-2620 brain PET imaging(1 day)
  • Neurocognitive deficits present in military personnel with blast-related mTBI as measured with NICoE(up to 4 weeks)

研究者

发起方
Life Molecular Imaging SA
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验